The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis
Open accessAbstract
Background: Estrogen replacement therapy (ERT) is a common treatment method for menopausal syndrome, however, its therapeutic value for the treatment of neurological diseases is still unclear. Epidemiological studies were performed and the effect of postmenopausal ERT on treating neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), was summarized by meta-analysis. Methods: 21 articles were selected by systematical searching of contents enlisted on PubMed and Web of Science before June 1, 2019. Epidemiological studies were extracted and relevant research data was obtained from the original articles based on the predefined inclusion criteria and data screening principles. The Comprehensive Meta-Analysis Version 2 software was used to pool effective size, test heterogeneity, conduct meta-regression and subgroup analysis, and calculate publication bias. Results: Our results showed that ERT significantly decreased the risk of onset and/or developing of AD (OR: 0.672; 95% CI: 0.581-0.779; P﹤0.001) and PD (OR: 0.470; 95% CI: 0.368-0.600; P﹤0.001) compared with the control group. Subgroup and meta-regression analysis showed that study design and measure of effect were the source of heterogeneity. Age, sample size, hormone therapy ascertainment, duration of the treatment or route of administration did not play a significant role in affecting the outcome of the meta-analysis. Conclusion: We presented evidence here to support the use of estrogen therapy for the treatment of AD and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448 · cited 1×
“Neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are characterized by the sustained cell cycle arrest and production of a continuous senescence-associated secretory phenotype due to structural and functional changes in neurons (Kritsilis et al., 2018).”
BackgroundProgesterone and Estrogen Regulate Oxidative Metabolism in Brain Mitochondria
Irwin, R. W., Yao, J., Hamilton, R. T., Cadenas, E., Brinton, R. D., & Nilsen, J. (2008) · Endocrinology · doi:10.1210/en.2007-1227 · Cited by 289
Research works printed but not linked: 47
- Ascherio, 2016, The epidemiology of Parkinson's disease: risk factors and prevention, Lancet. Neurol., 15, 1257, 10.1016/S1474-4422(16)30230-7 · DOI · Paper page
- Bagger, 2005, Early postmenopausal hormone therapy may prevent cognitive impairment later in life, Menopause, 12, 12, 10.1097/00042192-200512010-00005 · DOI · Paper page
- Becker, 1999, Gender differences in dopaminergic function in striatum and nucleus accumbens, Pharmacol. Biochem. Behav., 64, 803, 10.1016/S0091-3057(99)00168-9 · DOI · Paper page
- Brenner, 1994, Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study, Am. J. Epidemiol., 140, 262, 10.1093/oxfordjournals.aje.a117245 · DOI · Paper page
- Broe, 1990, A case-control study of Alzheimer's disease in Australia, Neurology, 40, 1698, 10.1212/WNL.40.11.1698 · DOI · Paper page
- Currie, 2004, Postmenopausal estrogen use affects risk for Parkinson disease, Arch Neurol., 61, 886, 10.1001/archneur.61.6.886 · DOI · Paper page
- Fernandez, 2000, Estrogen use among nursing home residents with a diagnosis of Parkinson's disease, Mov. Disord., 15, 1119, 10.1002/1531-8257(200011)15:6<1119::aid-mds1009>3.0.co;2-0 · DOI
- Graves, 1990, A case-control study of Alzheimer's disease, Ann. Neurol., 28, 766, 10.1002/ana.410280607 · DOI · Paper page
- Henderson, 2005, Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age, J. Neurol. Neurosurg. Psychiatry, 76, 103, 10.1136/jnnp.2003.024927 · DOI · Paper page
- Hogervorst, 2000, The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis, Neuroscience, 101, 485, 10.1016/S0306-4522(00)00410-3 · DOI · Paper page
- Imtiaz, 2017, Risk of Alzheimer's disease among users of postmenopausal hormone therapy: a nationwide case-control study, Maturitas, 98, 7, 10.1016/j.maturitas.2017.01.002 · DOI
- Kawas, 1997, A prospective study of estrogen replacement therapy and the risk of developing alzheimer's disease: the baltimore longitudinal study of aging, Neurology, 48, 1517, 10.1212/WNL.48.6.1517 · DOI · Paper page
- Labandeira-Garcia, 2016, Menopause and Parkinson's disease, Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. Front. Neuroendocrinol., 43, 44, 10.1016/j.yfrne.2016.09.003 · DOI
- Lau, 2010, Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia, Alzheimer Dis. Assoc. disord., 24, 56, 10.1097/WAD.0b013e31819d6ec9 · DOI
- Liu, 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat. Rev. Neurol., 9, 106, 10.1038/nrneurol.2012.263 · DOI · Paper page
- Martignoni, 2003, Reproductive life milestones in women with Parkinson's disease, Funct. Neurol., 18, 211
- Martins, 2014, Induction of NAFLD with increased risk of obesity and chronic diseases in developed countries, Open J. Endocr. Metab. Dis., 4, 90, 10.4236/ojemd.2014.44011 · DOI
- Martins, 2015, Nutritional and genotoxic stress contributes to diabetes and neurodegenerative diseases such as Parkinson's and Alzheimer's diseases, CNS Neurol. Disord., 3, 158, 10.2174/9781608059263114030008 · doi:10.2174/9781608059263114030008
- Martins, 2018, Top 10 Contributions on Genetics, 2
- Mortel, 1995, Lack of postmenopausal estrogen replacement therapy and the risk of dementia, J. Neuropsychiatry Clin. Neurosci., 7, 334, 10.1176/jnp.7.3.334 · DOI
- Mulnard, 2000, Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial, JAMA, 283, 1007, 10.1001/jama.283.8.1007 · DOI · Paper page
- Nicoletti, 2007, Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial, Clin. Neuropharmacol., 30, 276, 10.1097/wnf.0b013e318050c9f9 · DOI
- Nilsson, 2011, Development of subtype-selective oestrogen receptor-based therapeutics, Nat. Rev. Drug Discov., 10, 778, 10.1038/nrd3551 · DOI · Paper page
- O'Brien, 2014, Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease, Epidemiol. Rev., 36, 83, 10.1093/epirev/mxt008 · DOI
- Paganini-Hill, 1994, Estrogen deficiency and risk of Alzheimer's disease in women, Am. J. Epidemiol., 140, 256, 10.1093/oxfordjournals.aje.a117244 · DOI · Paper page
- Park, 2018, Lifetime exposure to estrogen and progressive supranuclear palsy: environmental and genetic PSP study, Mov. Disord., 33, 468, 10.1002/mds.27336 · DOI
- Picillo, 2017, The relevance of gender in Parkinson's disease: a review, J. Neurol., 264, 1583, 10.1007/s00415-016-8384-9 · DOI · Paper page
- Pike, 2017, Sex and the development of Alzheimer's disease, J. Neurosci. Res., 95, 671, 10.1002/jnr.23827 · DOI · Paper page
- Ragonese, 2004, Risk of Parkinson disease in women: effect of reproductive characteristics, Neurology, 62, 2010, 10.1212/WNL.62.11.2010 · DOI · Paper page
- Ramirez, 2003, Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice, Neuroendocrinology, 77, 223, 10.1159/000070277 · DOI
- Roberts, 2006, Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings, Alzheimer Dis. Assoc. Dis., 20, 141, 10.1097/00002093-200607000-00004 · DOI
- Rugbjerg, 2013, Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark, Parkinsonism Relat. Dis., 19, 457, 10.1016/j.parkreldis.2013.01.008 · DOI
- Seshadri, 2001, Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease, Arch. Neurol., 58, 435, 10.1001/archneur.58.3.435 · DOI
- Shao, 2012, Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study, Neurology, 79, 1846, 10.1212/WNL.0b013e318271f823 · DOI · Paper page
- Shumaker, 2003, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA, 289, 2651, 10.1001/jama.289.20.2651 · DOI · Paper page
- Slooter, 1999, Estrogen use and early onset Alzheimer's disease: a population-based study, J. Neurol. Neurosurg. Psychiatry, 67, 779, 10.1136/jnnp.67.6.779 · DOI
- Slopien, 2018, Menopause and diabetes: EMAS clinical guide, Maturitas, 117, 6, 10.1016/j.maturitas.2018.08.009 · DOI
- Struble, 2003, Regionally specific modulation of brain apolipoprotein E in the mouse during the estrous cycle and by exogenous 17β estradiol, Exp. Neurol., 183, 638, 10.1016/S0014-4886(03)00215-2 · DOI
- Szmuilowicz, 2009, Influence of menopause on diabetes and diabetes risk, Nat. Rev. Endocrinol., 5, 553, 10.1038/nrendo.2009.166 · DOI
- Tang, 1996, Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease, Lancet, 348, 429, 10.1016/S0140-6736(96)03356-9 · DOI · Paper page
- Venetsanaki, 2019, Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic perspectives, Curr. Vasc. Pharmacol., 17, 546, 10.2174/1570161116666180711121949 · DOI
- Waring, 1999, Postmenopausal estrogen replacement therapy and risk of AD: a population-based study, Neurology, 52, 965, 10.1212/WNL.52.5.965 · DOI · Paper page
- Xing, 2013, Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer's disease, Prog. Neurobiol., 111, 53, 10.1016/j.pneurobio.2013.09.006 · DOI
- Yaffe, 1998, Estrogen therapy in postmenopausal women: effects on cognitive function and dementia, JAMA, 279, 688, 10.1001/jama.279.9.688 · DOI · Paper page
- Yesufu, 2007, Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women, Womens Health, 3, 173, 10.2217/17455057.3.2.173 · DOI
- Zandi, 2002, Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study, JAMA, 288, 2123, 10.1001/jama.288.17.2123 · DOI · Paper page
- Zhao, 2011, Estrogen receptor beta-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause, Menopause, 18, 1131, 10.1097/gme.0b013e3182175b66 · DOI
Cited by
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Role of estrogen receptors in health and disease
Chen, P., Li, B., & Ou-Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839005 · Cited by 339
Exploring Sex-Related Differences in Microglia May Be a Game-Changer in Precision Medicine
Lynch, M. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.868448 · Cited by 146
Phytotherapy: A promising approach for the treatment of Alzheimer's disease
John, O. O., Amarachi, I. S., Chinazom, A. P., Adaeze, E., Kale, M. B., Umare, M. D., & Upaganlawar, A. B. (2022) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100030 · Cited by 69
The Interaction Between NF-κB and Estrogen in Alzheimer’s Disease
Mishra, P., Davies, D. A., & Albensi, B. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03152-3 · Cited by 51
Metadata
- Authors
- Song, Y.-J., Li, S.-R., Li, X.-W., Chen, X., Wei, Z.-X., Liu, Q.-S., & Cheng, Y.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2020-03-10
- Volume
- 14
- Pages
- 157-157
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W3011020391
- Cited by
- 167
- References
- 4
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis. https://app.cochat.ai/papers/10.3389/fnins.2020.00157
- The paper
- Song, Y.-J., Li, S.-R., Li, X.-W., Chen, X., Wei, Z.-X., Liu, Q.-S., & Cheng, Y. (2020). The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2020.00157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.